

[ Fri, May 07th 2021
] - WOPRAI
[ Fri, May 07th 2021
] - WOPRAI
[ Fri, May 07th 2021
] - WOPRAI
[ Fri, May 07th 2021
] - WOPRAI
[ Fri, May 07th 2021
] - WOPRAI
[ Fri, May 07th 2021
] - WOPRAI

[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
Jeffrey Hung Maintained (ACAD) at Buy with Increased Target to $29 on, May 6th, 2021
Jeffrey Hung of Morgan Stanley, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Increased Target from $28 to $29 on, May 6th, 2021.
Jeffrey has made no other calls on ACAD in the last 4 months.
There are 11 other peers that have a rating on ACAD. Out of the 11 peers that are also analyzing ACAD, 9 agree with Jeffrey's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Andrew Fein of "HC Wainwright & Co." Downgraded from Strong Buy to Hold and Decreased Target to $18 on, Wednesday, April 7th, 2021
- Chris Howerton of "Jefferies" Downgraded from Strong Buy to Hold and Decreased Target to $21 on, Tuesday, April 6th, 2021
- Salveen Richter of "Goldman Sachs" Downgraded from Strong Buy to Hold and Decreased Target to $25 on, Tuesday, April 6th, 2021
- Sumant Kulkarni of "Canaccord Genuity" Downgraded from Strong Buy to Hold and Decreased Target to $26 on, Tuesday, April 6th, 2021
- Vamil Divan of "Mizuho" Downgraded from Strong Buy to Hold and Held Target at $25 on, Tuesday, April 6th, 2021
- Tazeen Ahmad of "B of A Securities" Downgraded from Strong Buy to Hold on, Wednesday, March 10th, 2021
- Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold on, Tuesday, March 9th, 2021
- Neena Bitritto-Garg of "Citigroup" Downgraded from Strong Buy to Hold and Decreased Target to $35 on, Tuesday, March 9th, 2021
- Paul Matteis of "Stifel" Downgraded from Strong Buy to Hold and Decreased Target to $27 on, Tuesday, March 9th, 2021
These are the ratings of the 2 analyists that currently disagree with Jeffrey
- Joseph Stringer of "Needham" Maintained at Strong Buy with Decreased Target to $30 on, Monday, April 5th, 2021
- Danielle Brill of "Raymond James" Downgraded from Strong Buy to Buy and Decreased Target to $35 on, Tuesday, March 9th, 2021
Contributing Sources